KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Treasury Shares (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 16 years of Treasury Shares data on record, last reported at $4.8 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 77.78% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, up 77.78%, while the annual FY2025 figure was $4.8 million, 77.78% up from the prior year.
  • Treasury Shares reached $4.8 million in Q4 2025 per VRTX's latest filing, up from $4.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.3 million in Q4 2021 and bottomed at $300000.0 in Q1 2024.
  • Average Treasury Shares over 5 years is $2.1 million, with a median of $1.8 million recorded in 2025.
  • Peak YoY movement for Treasury Shares: tumbled 55.37% in 2023, then skyrocketed 650.0% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $5.3 million in 2021, then crashed by 45.04% to $2.9 million in 2022, then crashed by 55.37% to $1.3 million in 2023, then surged by 107.69% to $2.7 million in 2024, then surged by 77.78% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $4.8 million in Q4 2025, $4.5 million in Q3 2025, and $1.8 million in Q2 2025.